Screening of NCI-DTP Library to Identify New Drug Candidates for Borrelia burgdorferi
Nature Publishing Group (Macmillan Publishers Limited)
Journal of Antibiotics
Lyme disease is the most rapidly growing tick borne zoonotic disease of the Northern Hemisphere and is among the 10 most commonly reported nationally notifiable diseases in the United States.1 Clinical presentations include erythema migrans, fever, chills, muscle and joint pain.2, 3 Though these symptoms tend to fade away even without therapeutic intervention, a significant number of untreated patients develop arthritis and persistent myalgia following exposure to Borrelia burgdorferi.4 Furthermore, 10–20% of patients treated for Lyme disease develop symptoms considered typical, or even exaggerated, including muscle, joint pain and generalized fatigue5, 6. This condition is referred as post-treatment lyme disease syndrome (PTLDS).
Pothineni, Venkata Raveendra; Wagh, Dhananjay; Babar, Mustafeez Mujtaba; Inayathullah, Mohammed; Watts, R. Edward; Kim, Kwang-Min; Parekh, Mansi B.; Gurjarpadhye, Abhijit Achyut; Solow-Cordero, David; Tayebi, Lobat; and Rajadas, Jayakumar, "Screening of NCI-DTP Library to Identify New Drug Candidates for Borrelia burgdorferi" (2017). School of Dentistry Faculty Research and Publications. 190.